DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contr ...

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review ...

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 - 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in ...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated ...

Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive twenty-four month results from its Open-Label ...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: ...

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq ...